Authentica Global
Markets S&P 500 7,543.64 ▲ 0.81% Nasdaq 26,206.89 ▲ 1.30% Dow Jones 52,487.41 ▲ 0.27% US 10 Yr 4.54 ▼ 0.66% Crude Oil 71.87 ▼ 0.29% Gold 4,131.40 ▼ 0.23% Bitcoin 63,175 ▲ 1.51% FTSE 100 10,472.45 ▼ 0.16% EUR/USD 1.1436 ▲ 0.02% Nikkei 225 67,743.85 ▲ 1.38%
Topic archive

orforglipron

Reporting, analysis and commentary on orforglipron from Authentica Global, drawn together from across our coverage.

1 article Latest update: 5 Jul 2026 1 section
Related sections Health
Related topics Eli Lilly Foundayo weight loss pill Medicare GLP-1 drugs obesity treatment weight loss health policy
Tag lead
A pharmacist holding a bottle of Eli Lilly Foundayo orforglipron oral weight loss tablets at a pharmacy counter
Health

How the Eli Lilly Foundayo Weight Loss Pill Reaches Medicare Patients for a $50 Copay

Foundayo, Eli Lilly's oral GLP-1 pill approved by the FDA on April 1, 2026, becomes available to eligible Medicare beneficiaries for a flat $50 monthly copay starting July 1 under a federal demonstration program running through 2027.

5 Jul 2026 ·8 min read
Keep reading

More paths through this story

This archive gathers Authentica Global coverage of orforglipron, bringing together the reporting, analysis and commentary connected to the subject.

Related topics

Eli Lilly Foundayo weight loss pill Medicare GLP-1 drugs obesity treatment weight loss health policy Federal Reserve Donald Trump AI infrastructure nonfarm payrolls

Related sections

Health

Latest nearby

Health · 5 Jul 2026 Colorado Enbrel Price Cap Blocked, Pharma Pockets the Win Health · 5 Jul 2026 US Measles Elimination Status 2026 Cracks at 2,170 Cases Health · 5 Jul 2026 Aetna, Cigna Headline ACA Marketplace Insurers Exit 2026 Health · 5 Jul 2026 Dead Skua Marks First H5N1 Bird Flu Australia Detection